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Accumulation of advanced glycation endproducts (AGEs) in bone tissue occurs in ageing and in
Diabetes mellitus, and is partly responsible for the increased risk of low-stress bone fractures observed
in these conditions. In this study we evaluated whether the anti-osteoporotic agent strontium ranelate
can prevent the deleterious effects of AGEs on bone cells, and possible mechanisms of action involved.
Using mouse MC3T3E1 osteoblastic cells in culture we evaluated the effects of 0.1 mM strontium
ranelate and/or 100 mg/ml AGEs-modified bovine serum albumin (AGEs-BSA) on cell proliferation,
osteogenic differentiation and pro-inflammatory cytokine production. We found that AGEs-BSA alone
decreased osteoblastic proliferation and differentiation (Po0.01) while increasing IL-1b and TNFa
production (Po0.01). On its own, strontium ranelate induced opposite effects: an increase in osteoblast
proliferation and differentiation (Po0.01) and a decrease in cytokine secretion (Po0.01). Additionally,
strontium ranelate prevented the inhibitory and pro-inflammatory actions of AGEs-BSA on osteoblastic
cells (Po0.01). These effects of strontium ranelate were blocked by co-incubation with either the
MAPK inhibitor PD98059, or the calcium channel blocker nifedipine. We also evaluated by Western
blotting the activation status of ERK (a MAPK) and b-catenin. Activation of both signaling pathways was
decreased by AGEs treatment, and this inhibitory effect was prevented if AGEs were co-incubated with
strontium ranelate (Po0.01). On its own, strontium ranelate increased both pERK and activated
b-catenin levels. In conclusion, this study demonstrates that strontium ranelate can prevent the
deleterious in vitro actions of AGEs on osteoblastic cells in culture by mechanisms that involve calcium
channel, MAPK and b-catenin activation.
& 2013 Elsevier B.V. All rights reserved.1. Introduction
Bone is a dynamic tissue that undergoes continuous remodelling
throughout the entire life span (Manolagas and Parfitt, 2010). This
highly regulated process can be affected by different conditions such
as ageing, chronic diseases and pharmacological treatment. In
particular, it has been demonstrated that Diabetes mellitus can
affect the quality of bone tissue causing an increase in low-stress
fractures (Vestergaard et al., 2005), although the exact causes of
these alterations are not fully understood. It has been suggested that
the accumulation of advanced glycation endproducts as a result of
high glucose levels could be an important factor to develop bone
alterations (McCarthy et al., 1997; Vlassara and Palace, 2002). We
have previously demonstrated that advanced glycation endproducts
inhibit osteoblastic proliferation and differentiation (McCarthy et al.,
1997,, 2001b). The biological effects of advanced glycationll rights reserved.
x33.endproducts are mediated by their recognition by specific receptors
that in turn induce an increase in receptor expression, activate
reactive oxygen species production, mitogen-activated protein
kinases and an increase in apoptosis (Alikhani et al., 2007;
Gangoiti et al., 2008; McCarthy et al., 2001b; Mercer et al., 2004).
Binding of advanced glycation endproducts to these specific recep-
tors can increase the secretion of pro-inflammatory cytokines such
as interleukin-6 and tumor necrosis factor-a (TNFa), which could
directly affect bone homeostasis (Bierhaus et al., 2005; Franke et al.,
2011; Mosquera, 2010; Takagi et al., 1997). In inflammatory condi-
tions or ageing these cytokines stimulate the expression of RANKL
by osteoblasts, thus contributing to the recruitment and activation
of osteoclasts that in turn could contribute to bone loss (Franke
et al., 2011; Manolagas and Parfitt, 2010; Schett, 2011). We have
previously demonstrated that some of these deleterious in vitro
actions of advanced glycation endproducts on osteoblasts can be
prevented by co-treatment with low doses of potent anti-
osteoporotic N-containing biphosphonates, as well as by co-
treatment with the insulin sensitizer metformin (Gangoiti et al.,
2008; Schurman et al., 2008).
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strontium ranelate, which has been reported to induce both anabolic
and anti-resorptive effects on bone (Ammann, 2005; Fonseca, 2008;
Marie, 2010). It has been demonstrated that strontium ranelate can
exert its action in part by activation of the calcium-sensing receptor,
which can thus stimulate various intracellular pathways such as
extracellular-regulated kinases (ERK), cyclooxigenases, and Wnt
signalling (Chattopadhyay et al., 2007; Choudhary et al., 2007).
Activation of the calcium-sensing receptor by strontium ranelate
induces genes related to osteoblastic growth and maturation
(Caverzasio, 2008; Chattopadhyay et al., 2007; Choudhary et al.,
2007; Zhu et al., 2007).
In the present work we have evaluated the effects of strontium
ranelate on the deleterious action of advanced glycation end-
products on osteoblastic cells in culture of mouse origin. We have
also investigated the effect of advanced glycation endproducts
and/or strontium ranelate on the activation of calcium channels,
extracellular-regulated kinases and b-catenin in osteoblastic cells,
and on their secretion of proinflammatory cytokines.2. Material and methods
2.1. Preparation of advanced glycation endproducts
Advanced glycation endproducts-modified bovine serum albu-
min was prepared by incubation of 10 mg/ml bovine serum
albumin (bovine serum albumin, Sigma, Argentina) with 33 mM
d glycolaldehyde in 150 mM phosphate-buffered saline pH 7.4 at
37 1C for 3 days under sterile conditions, after which unincorpo-
rated sugar was removed (Gangoiti et al., 2008). Control bovine
serum albumin was incubated in the same conditions without
sugar. The formation of advanced glycation endproducts was
assessed with a Shimadzu spectrofluorometer by their character-
istic fluorescence—emission maximum at 420 nm upon excita-
tion at 340 nm. The estimated levels of advanced glycation
endproducts-modified bovine serum albumin obtained in this
in vitro incubation were 18.5% relative fluorescence intensity/mg
protein, in contrast to 3.2% for control bovine serum albumin.
2.2. Cell culture and incubations
MC3T3E1 mouse calvaria-derived cells were grown in Dulbec-
co’s–Eagle’s Modified Media (DMEM, LabVet, Argentina) contain-
ing 10% FBS (Natocor, Argentina), 100 U/ml penicillin and 100 mg/
ml streptomycin at 37 1C in a 5% CO2 atmosphere (McCarthy et al.,
1997). In the non-transformed MC3T3E1 cells, previous studies
have demonstrated that expression of osteoblastic markers begins
after culturing the cells with medium supplemented by 5 mM
b-glycerol-phosphate (bGP, Sigma, Argentina) and 145 mM ascor-
bic acid (AA, Sigma, Argentina) (Quarles et al., 1992). For pro-
liferation and differentiation experiments, cells seeded on multi-
well plates were incubated in DMEM medium with different
doses of control bovine serum albumin or advanced glycation
endproducts-modified bovine serum albumin, with or without
strontium ranelate (kindly provided by Servier, Argentina), and in
the presence or absence of Nifedipine or PD98059, for the periods
of time indicated in the legends of figures. For ALP expression and
type I collagen production experiments with MC3T3E1 osteo-
blasts, cells were cultured for 1 week in DMEM/Fetal bovine
serum supplemented with bGP and AA changing the medium
every 2 days, after which the differentiation medium was chan-
ged and cells were incubated with different doses of non gly-
cated- bovine serum albumin or advanced glycation endproducts-
modified bovine serum albumin, with or without strontium
ranelate, for an additional 72 h.2.3. Cell proliferation assay
Cell proliferation was determined using the crystal violet (Sigma,
Argentina) mitogenic bioassay as described previously (Gangoiti
et al., 2008). Briefly, cells were incubated with different concentra-
tions of strontium ranelate in serum-free DMEM, according to the
figure legends. Then, the monolayers were fixed with 5% glutar-
aldehyde, stained with 0.5% crystal violet/25% methanol and the dye
taken up by the cells was extracted using 0.5 ml/well 0.1 M glycine/
HCl buffer, pH 3.0/30% methanol. Absorbance was read at 540 nm
after a convenient sample dilution.
2.4. Assays for osteoblastic differentiation
Osteoblastic differentiation was evaluated by two markers: ALP
and the quantitation of type I collagen production, as we have
previously described (Molinuevo et al., 2010). Cells were washed
with PBS and solubilised in 0.5 ml 0.1% Triton X-100. Aliquots of the
total cell extract were used for colorimetric protein determination
(Bradford, 1976). Measurement of ALP was carried out by spectro-
photometric determination at 405 nm of hydrolysis of para-
nitrophenyl-phosphate (Sigma, Argentina) to para-nitrophenol
(pNP) at 37 1C for 10 min. Under the same experimental conditions,
collagen production was evaluated with a Sirius red-based colori-
metric micro-assay (Molinuevo et al., 2010): cells were fixed in
Bouin’s fluid for 1 h, washed with water and stained with Sirius Red
(Sigma, Argentina) dye for 1 h. The stained material was dissolved in
0.1 N sodium hydroxide and absorbance read at 550 nm.
2.5. Western blot analysis of pERK and b-catenin
In these experiments, osteoblastic cells growing in serum-free
medium with the addition of different concentrations of strontium
ranelate with or without 10 mM nifedipine were lysated in Laemmli
et al. (1976) and the protein content was evaluated by the method of
Lowry et al. (1951). These lysates were heated at 100 1C for 3 min and
aliquots corresponding to 30 mg of total protein were subjected to
12% SDS-PAGE. After washing and blocking, the membranes were
incubated either with an anti-pERK antibody (Santa Cruz, Argentina),
with a polyclonal antibody that recognizes phosphorylated isoform of
ERK, or with an anti-actin antibody; or with antibodies against either
the active isoform of b-catenin or total b-catenin (Micropore). The
intensity of the specific bands was quantified by densitometry after
scanning of the membranes. Images were analysed using the gels
plugin of MBF_Image J (http://www.macbiophotonics.ca).
2.6. ELISA assay for interleukin 1b and tumour necrosis factor a
Osteoblastic cells were incubated during 24 h with either control
bovine serum albumin or advanced glycation endproducts-modified
albumin, with or without strontium ranelate, and in the presence or
absence of 10 mM nifedipine. Interleukin 1-b (IL-1b) and tumor
necrosis factor-a (TNFa) were evaluated in the conditioned media
with a commercial ELISA kit (Mouse IL-1b ELISA Kit, OptEIATM from
BD Biosciences and Mouse TNF-a ELISA Kit, OptEIATM) using
3,30,5,50-tetrametilbenzidine from BD Biosciences kit as a chromo-
genic substrate (Cortizo et al., 2012).
2.7. Statistical analysis
Three independent experiments were run for each experimen-
tal condition. Results are expressed as the mean7S.E.M. One Way
ANOVA with Dunnett’s post test was performed using GraphPad
InStat version 3.05.GraphPad Software, San Diego, California USA;
Po0.05 was considered to be statistically significant when
compared with untreated control (0 mM strontium ranelate).
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3.1. Effect of advanced glycation endproducts and strontium
ranelate on osteoblastic cell proliferation
Since strontium ranelate has been shown to exert an anabolic
effect on bone tissue (Marie, 2010), we evaluated its effect on
MC3T3E1 osteoblastic cell growth. In our experimental condi-
tions, strontium ranelate dose-dependently increased osteoblastic
cell proliferation (Fig. 1A).
We found opposite results for glycated albumin: namely, that 100
and 200 mg/ml advanced glycation endproducts-modified albumin
significantly inhibited MC3T3E1 cell proliferation when compared
with non-glycated bovine serum albumin (Fig. 1B). In view of the
opposing effects observed, we next evaluated whether strontium
ranelate could prevent the anti-proliferative action of advanced
glycation endproducts in this cell line. In co-incubation experiments,
we found that 0.1 mM strontium ranelate was able to prevent the
deleterious action of advanced glycation endproducts (Fig. 1B). The
choice of this concentration of strontium ranelate is especielly
relevant, since it coincides with the dose of the drug that has been
found in the serum of post-menopausal women treated with stron-
tium ranelate (Marie, 2008).
3.2. Action of advanced glycation endproducts and strontium
ranelate on osteoblastic differentiation. role of calcium channels and
extracellular signal—regulated kinases
In further experiments we investigated the effect of strontium

































































Fig. 1. Effect of Strontium ranelate on osteoblastic cell proliferation and differentiation.
conditions. (B) Strontium ranelate (0.1 mM) stimulated cell proliferation in bovine seru
and 200 mg/ml advanced glycation endproducts in culture. (C) Type I collagen produc
(D) Alkaline phosphatase activity. Results represent the mean7S.E.M., n¼4, ]Po0.05 vs
vs. advanced glycation endproducts. SR: Strontium ranelate. AGE: advanced glycationdifferentiation, namely cell-associated collagen production and
ALP activity. Advanced glycation endproducts (100 mg/ml) inhib-
ited osteoblastic differentiation (Fig. 1C and D). On the other
hand, we found that 0.1 mM strontium ranelate increased both
type I collagen production (Fig. 1C) and ALP activity (Fig. 1D)
when compared to control bovine serum albumin (100 mg/ml).
Moreover, 0.1 mM strontium ranelate significantly prevented the
inhibition of osteoblastic differentiation caused by advanced
glycation endproducts (Fig. 1C and D).
It has been proposed that the action of strontium ranelate is
mediated by the activation of calcium channels (Caverzasio,
2008). We found that 10 mM nifedipine was able to block the
increase of type I collagen and ALP activity induced by 0.1 mM of
strontium ranelate compared to control condition (bovine serum
albumin) (Fig. 2A and B). Similarly, the co-incubation of nifedi-
pine with strontium ranelate and advanced glycation endproducts
blunted the increase of differentiation parameters induced by
strontium ranelate (Fig. 2A and B).
In another series of experiments, we found that strontium
ranelate—induced type I collagen production was mediated by
ERK pathway, since this effect could be blocked by co-incubation
with 0.5 mM PD98059 (Fig. 2C). As already mentioned, advanced
glycation endproducts induced a decrease in type I collagen
production, an action that was prevented by co-incubation with
0.1 mM strontium ranelate. This preventive effect of strontium
ranelate could also be blocked by incubation with PD98059
(Fig. 2C).
When we investigated the activation of ERK by Western blot
analysis, we found that 0.1 mM strontium ranelate induced the








































































(A) Strontium ranelate stimulated cell proliferation in all doses studied under basal
m albumin (100 mg/ml) treated cells, and prevented the deleterious action of 100
tion, expressed as a % of the basal condition with bovine serum albumin alone.
. Basal; nPo0.01 vs. Basal; aPo0.05 vs. advanced glycation endproducts; bPo0.01
endproducts-modified bovine serum albumin. BSA: bovine serum albumin.
Fig. 2. Mechanisms regulating the effect of strontium ranelate on osteoblastic cell differentiation. The L-type calcium channel blocker nifedipine (10 mM) inhibits the
action of strontium ranelate on type I collagen production (A) and alkaline phosphatase activity (B). The blockade of ERK pathway with 0.5 mM PD98059 inhibits the effect
of strontium ranelate on type I collagen production (C). Osteoblastic cells were differentiated in an osteogenic medium as indicated in Section 2, in the presence of
100 mg/ml bovine serum albumin or 100 mg/ml advanced glycation endproducts with or without 0.1 mM strontium ranelate and/or each inhibitor. Results represent the
mean7S.E.M., n¼6; ]Po0.05 vs. Basal; nPo0.01 vs. Basal; nnPo0.001 vs. Basal; nPo0.01 as indicated. SR: Strontium ranelate. AGE: advanced glycation endproducts-
modified bovine serum albumin. BSA: bovine serum albumin.
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The co-incubation of advanced glycation endproducts with stron-
tium ranelate increased the activation of ERK to levels similar to
those with strontium ranelate alone (Fig. 3). In addition, we
demonstrated that these effects were mediated by calcium
channels since 10 mM nifedipine was able to abolish the stron-
tium ranelate-induced activation of ERK, both in the presence or
absence of advanced glycation endproducts (Fig. 3).
3.3. Actions of strontium ranelate, advanced glycation endproducts
and nifedipine on b-catenin activation
In order to evaluate the Wnt pathway we investigated the
activation of its downstream mediator b-catenin. We found that
0.1 mM strontium ranelate stimulated b-catenin activation
(Fig. 4). On the contrary, advanced glycation endproducts sig-
nificantly inhibited b-catenin activation, an effect that was pre-
vented by co-incubation with 0.1 mM strontium ranelate (Fig. 4).
All these effects of strontium ranelate (alone or with advanced
glycation endproducts) on b-catenin activation were inhibited by
10 mM nifedipine (Fig. 4).
3.4. Modulation of cytokine secretion by strontium ranelate and
advanced glycation endproducts
We also investigated possible changes in the osteoblastic
secretion to culture media of IL-1b and TNFa, induced by different
experimental conditions. In control conditions (100 mg/ml bovine
serum albumin) strontium ranelate significantly inhibited bothIL-1b and TNFa secretion (Fig. 5A and B, respectively). We also
found that 100 mg/ml advanced glycation endproducts signifi-
cantly increased the secretion of IL-1b (Fig. 5A) and TNFa (Fig. 5B)
to the culture media when compared with bovine serum albumin.
This increase in the secretion of both interleukins caused by
advanced glycation endproducts was completely abolished by
co-incubation with 0.1 mM strontium ranelate (Fig. 5A and B).
The preventive action of strontium ranelate on the increase of IL-
1b and TNFa secretion induced by advanced glycation endpro-
ducts was partially blocked by co-treatment with 10 mM nifedi-
pine (Fig. 5A and B). However, nifedipine treatment with either
bovine serum albumin or advanced glycation endproducts (i.e,
without strontium ranelate) induced no effect on the secretion of
IL-1b (Fig. 5A), and only partially inhibited the secretion of TNFa
induced by advanced glycation endproducts (Fig. 5B).4. Discussion
Bone is a metabolically active tissue that is constantly remodeled
throughout the entire lifespan, in a dynamic and tightly coupled
process involving bone formation by osteoblasts and bone resorp-
tion by osteoclasts. This process can be modulated by different
hormones and cytokines that induce or inhibit bone formation and/
or resorption (Kwan Tat et al., 2004; Lambert et al., 2007) It has
previously been demonstrated that bone turnover in diabetic
patients is altered, causing an increase in bone fragility and as a
consequence an increase in fracture incidence (Krakauer et al., 1995;
Vestergaard et al., 2005). The reasons for this alteration are unclear,
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Fig. 3. Strontium ranelate increases pERK levels through the activation of calcium
channels. Osteoblastic cells were treated with 100 mg/ml bovine serum albumin or
100 mg/ml advanced glycation—end products with or without strontium ranelate
and/or 10 mM nifedipine for 1 h and pERK levels were analyzed by Western blot.
Results are expressed as a % of the basal condition (bovine serum albumin) and
represent the mean7S.E.M., n¼4; nPo0.01 vs. Basal. SR: Strontium ranelate.
AGE: advanced glycation endproducts-modified bovine serum albumin. BSA:
bovine serum albumin.
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Fig. 4. Prevention by strontium ranelate of advanced glycation endproducts
inhibition of b-catenin activation. This effect of strontium ranelate is abolished
by co-incubation with 10 mM nifedipine. Results are expressed as a % of the basal
condition (bovine serum albumin) and represent the mean7S.E.M., n¼4;
]Po0.05 vs. Basal; yPo0.01 vs. advanced glycation endproducts. SR: Strontium
ranelate. AGE: advanced glycation endproducts-modified bovine serum albumin.



























































Fig. 5. Strontium ranelate inhibits cytokine production induced by advanced
glycation endproducts. This effect is dependent on the activation of L-type calcium
channels. (A) IL-1b production and (B) TNFa production. Results represent the
mean7S.E.M., n¼4; ]Po0.05 vs. Basal; nPo0.01 vs. Basal; yPo0.01 vs. advanced
glycation endproducts; nPo0.05 vs. advanced glycation endproducts; aPo0.05 vs.
AGEþSR; bPo0.01 vs. AGEþSR. SR: Strontium ranelate. AGE: advanced glycation
endproducts-modified bovine serum albumin. BSA: bovine serum albumin.
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of the causes could be the accumulation of advanced glycation
endproducts on the organic matrix of bone, mainly type 1 collagen(McCarthy et al., 2001a; Wongdee and Charoenphandhu, 2011).
We have previously demonstrated that glycated collagen impairs
osteoblastic attachment, spreading, maturation and mineralising
capacity (McCarthy et al., 1997,, 2001a,, 1999). We have also
demonstrated that soluble proteins such as albumin modified by
advanced glycation endproducts, can inhibit osteoblastic cell pro-
liferation and differentiation (McCarthy et al., 1997) and that this
deleterious action of advanced glycation endproducts on osteoblasts
can be prevented by different insulin-sensitizing or anti-resorptive
agents (Gangoiti et al., 2008; Schurman et al., 2008). In the present
work we have evaluated possible effects on osteoblastic cells in
culture, of the anti-osteoporotic agent strontium ranelate, alone or
in combination with advanced glycation endproducts. In line with
the findings of other authors (Fonseca, 2008; Marie, 2010), our
present results confirm that strontium ranelate on its own can act as
an anabolic agent on osteoblastic cells in culture, inducing their
proliferation and differentiation. In addition, we have found that
strontium ranelate is able to prevent the deleterious action of
advanced glycation endproducts on the proliferation, alkaline phos-
phatase activity and type-1collagen production of osteoblast—
like cells in culture. Our results indicate that these preventive effects
of strontium ranelate are mediated by the activation of calcium
J.M. Fernández et al. / European Journal of Pharmacology 706 (2013) 41–4746channels and, as a consequence, the activation of ERK and b-catenin.
Consistent with our results, other authors have proposed that the
anabolic action of strontium ranelate on osteoblasts is mediated by
the activation of ERK as well as Wnt pathway (Brown, 2003;
Fromigue et al., 2009; Marie, 2010).
Calcium is an abundant cation that is utilized for signal
transduction in most cell types. L-type calcium channels have
been shown to be highly expressed and physiologically active in
osteoblasts. Activation of these channels leads to an increase in
intracellular calcium levels, and this has been associated with
increased survival and functionality of osteoblasts (Blair et al.,
2007). Strontium ranelate has previously been demonstrated to
modulate intracellular calcium levels, via calcium sensor
receptor-dependent and independent pathways. Our present
results are in agreement with these proposed mechanisms: we
show that strontium ranelate blocks the deleterious action of
advanced glycation endproducts on osteoblastic cells by activat-
ing L-type calcium channels, and thus modulating the activation
of ERK and b-catenin.
Bone metabolic balance can be controlled by different cyto-
kines; some of them favour osteoblastic bone formation while
others promote bone resorption (Kwan Tat et al., 2004; Lambert
et al., 2007). In physiological or pathological conditions that
induce a systemic accumulation of advanced glycation endpro-
ducts (ageing, Diabetes mellitus, renal insufficiency, chronic
intake of excess dietary advanced glycation endproducts), there
is an increase in circulating pro-inflammatory cytokines such as
TNFa and IL-1b (Vlassara and Striker, 2011). These cytokines have
previously been found to induce osteoclastic development while
decreasing osteoblast activity and function (Kwan Tat et al., 2004;
Wongdee and Charoenphandhu, 2011), and so their imbalance
over a prolonged period of time could contribute to the develop-
ment of bone alterations. In the present study we have found that
strontium ranelate decreased the osteoblastic secretion of IL-1b
and TNFa. These results are in agreement with those of Boanini
et al. who found that strontium was able to decrease IL6 produc-
tion by osteoblasts (Boanini et al., 2011). It has previously been
demontrated that IL1b, IL6 and TNFa can control and influence
the expression of each other, and also synergistically stimulate
osteoblastic production of pro-osteoclastic factors such as RANKL
(Kwan Tat et al., 2004). In the present study, we have found that
advanced glycation endproducts increase the secretion of TNFa
and IL-1b by cultured osteoblastic cells, while co-incubation with
strontium ranelate prevents this increase.
In conclusion, we have demonstrated that strontium ranelate
can prevent the deleterious actions of advanced glycation end-
products on osteoblastic cells in culture. The mechanisms of
action involved include activation of L-type calcium channels,
upstream to the activation of ERK and b-catenin. On its own,
strontium ranelate decreases the osteoblastic secretion of pro-
inflammatory and pro-osteoclastic cytokines TNFa and IL-1b,
suggesting that in addition to its anabolic effect on bone it could
also have anti-catabolic actions. Our in vitro results thus suggest
that strontium ranelate could be an interesting option for the
treatment of low bone mass and/or increased bone fragility in
conditions associated with an accumulation of advanced glyca-
tion endproducts, due to its potential preventive effects on
advanced glycation endproducts-induced bone alterations, as well
as its combined anabolic and anti-catabolic effects.Declaration of interest
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